Filing Flows › Altria Group (MO) › Q2 2026 › vs Q1 2026
Altria Group (MO) Q2 2026 vs Q1 2026 (quarter over quarter)
Altria Group's revenue rose $683M (+13%) from $5.4B in Q1 2026 to $6.1B in Q2 2026. The biggest changes: Smokeable Products Segment +$634M (+13%); Oral Tobacco Segment +$44.0M (+7%); All Other +$5.0M (+500%). Gross margin 62.5% against 64.6% (-2.1 pts).
Altria Group, Q2 2026: revenue $6.1B (+0.1% year over year), operating margin 51.3%, net earnings $2.3B, operating cash flow $719M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 62.5% | 64.6% | -2.1 pts |
| Operating margin | 51.3% | 54.5% | -3.1 pts |
| Net margin | 37.6% | 40.2% | -2.6 pts |
| Free cash flow margin | 10.8% | 41.1% | -30.3 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Smokeable Products Segment | $5.4B | $4.8B | $634M | +13% |
| Oral Tobacco Segment | $713M | $669M | $44.0M | +7% |
| All Other | $6.0M | $1.0M | $5.0M | +500% |
| Revenue | $6.1B | $5.4B | $683M | +13% |
| Gross profit | $3.8B | $3.5B | $314M | +9% |
| Cost of revenue | $2.3B | $1.9B | $369M | +19% |
| Operating profit | $3.1B | $3.0B | $180M | +6% |
| Operating expenses | $684M | $550M | $134M | +24% |
| Pre-tax earnings | $2.9B | $2.9B | $70.0M | +2% |
| Other expense, net | $207M | $97.0M | $110M | +113% |
| Net earnings | $2.3B | $2.2B | $115M | +5% |
| Income tax | $631M | $676M | −$45.0M | -7% |
| Depreciation & amortization | $56.0M | $56.0M | $0 | 0% |
| Working capital & other | $1.6B | −$85.0M | $1.7B | — |
| Operating cash flow | $719M | $2.3B | −$1.6B | -69% |
| Free cash flow (OCF − capex) | $662M | $2.2B | −$1.6B | -70% |
| Capital expenditures | $57.0M | $93.0M | −$36.0M | -39% |
Questions
How much did Altria Group's revenue grow quarter over quarter in Q2 2026?
Altria Group's revenue rose $683M (+13%) from $5.4B in Q1 2026 to $6.1B in Q2 2026.
What drove Altria Group's revenue change in Q2 2026?
Smokeable Products Segment +$634M (+13%); Oral Tobacco Segment +$44.0M (+7%); All Other +$5.0M (+500%).